Bio-Rad Laboratories (BIO) 118.36 $BIO
Zacks Rank #5 Additions for Friday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 06, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Friday
AXE: 76.07 (+0.44), BIO: 118.36 (+0.79), BCE: 44.74 (+0.14), BITA: 62.95 (+2.85)
Bio-Rad to Report Fourth-Quarter and Full-Year 2014 Financial Results Thursday, February 26, 2015
Marketwired - Tue Feb 03, 5:57PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO.
, a global provider of life science research and clinical diagnostic products, will report financial results for the fourth quarter and full year 2014 on Thursday, February 26, 2015, after the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Standard Time (5 PM Eastern Standard Time) that day.
BIO: 118.36 (+0.79), BIO.B: 117.35 (unch)
Frost & Sullivan Recognizes Bio-Rad's Digital PCR Platform, the QX200(TM) AutoDG(TM) Droplet Digital(TM) PCR System For New Product Innovation
PR Newswire Europe - Wed Jan 28, 8:00AM CST
-- Bio-Rad's Automated Droplet Generator delivers trusted, high-quality results to a market characterized by increasingly stringent regulations and standards
BIO: 118.36 (+0.79)
Affymetrix's Preliminary Q4 Revenues Outshine Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 13, 4:35PM CST
Affymetrix Inc (AFFX) recently announced preliminary revenue expectation for the fourth quarter of 2014.
A: 40.15 (+0.13), BIO: 118.36 (+0.79), ILMN: 198.54 (+1.81), AFFX: 11.45 (+0.02)
Zacks Rank #5 Additions for Tuesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 13, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Tuesday
CRR: 40.35 (+2.73), COG: 28.10 (+0.18), BIO: 118.36 (+0.79), ARPI: 17.95 (-0.04), AEG: 7.55 (-0.08)
Affymetrix (AFFX) Touches 52-Week High on Bullish Trends - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 29, 8:02AM CST
Shares of Affymetrix Inc. (AFFX) scaled a 52-week high of $10.14 on Dec 26 and closed at $10.07, representing a healthy year-to-date return of approximately 14.4%, better than the S&P 500's return of 12.6% over the same period.
A: 40.15 (+0.13), BIO: 118.36 (+0.79), ILMN: 198.54 (+1.81), AFFX: 11.45 (+0.02)
Affymetrix, Binding Site Group Ink Distribution Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 4:25PM CST
Provider of life science tools and molecular diagnostic products, Affymetrix Inc. (AFFX), recently announced that its eBioscience business has entered into a multi-year distribution agreement with The Binding Site Group Ltd.
HBIO: 5.31 (-0.01), BIO: 118.36 (+0.79), ILMN: 198.54 (+1.81), AFFX: 11.45 (+0.02)
Affymetrix Axiom Genotyping Platform Selected by Toshiba - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 02, 5:10PM CST
The Axiom Genotyping Solution platform of Affymetrix (AFFX) has been selected by Toshiba's Healthcare Company as the platform for its newly launched genotyping service.
HBIO: 5.31 (-0.01), BIO: 118.36 (+0.79), ILMN: 198.54 (+1.81), AFFX: 11.45 (+0.02)
Zacks Rank #5 Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 26, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Wednesday
BUD: 121.72 (-0.80), BIO: 118.36 (+0.79), AVHI: 15.16 (+0.04), BBL: 48.82 (+2.36), WBAI: 17.36 (-0.30)
Bio-Rad Receives Premarket Application Approval for Its Geenius HIV 1/2 Supplemental Assay
Marketwired - Wed Nov 19, 3:45PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO. , a global provider of life science research and clinical diagnostic products life science research and clinical diagnostic products, today announced that it has received Premarket Application approval from the U.S. Food and Drug Administration for Bio-Rad's Geenius(TM) HIV 1/2 Supplemental Assay (test).
BIO: 118.36 (+0.79), BIO.B: 117.35 (unch)
SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Directors of Bio-Rad Laboratories, Inc.
PR Newswire - Wed Nov 12, 12:44PM CST
Levi & Korsinsky, LLP is investigating Bio-Rad Laboratories, Inc. ("Bio-Rad" or the "Company"
(NYSE: BIO) in connection with possible breaches of fiduciary duty by the Board of Directors of the Company.
BIO: 118.36 (+0.79)
Lifshitz & Miller Law Firm Announces Investigation of Barrett Business Services, Inc., Bio-Rad Laboratories, Inc., Pingtan Marine Enterprise Ltd., Rayonier Inc. and Salix Pharmaceuticals, Ltd.
PR Newswire - Tue Nov 11, 11:10AM CST
Barrett Business Services, Inc.
RYN: 28.02 (-1.15), BIO: 118.36 (+0.79), BBSI: 39.78 (+0.84), SLXP: 152.35 (+3.17), PME: 2.42 (-0.07)
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces an Investigation into Possible Breaches of Fiduciary Duties by the Board of Directors of Bio-Rad Laboratories, Inc.
Business Wire - Fri Nov 07, 3:39PM CST
Rigrodsky & Long, P.A. announces that it is investigating whether certain officers and directors of Bio-Rad Laboratories, Inc. ("Bio-Rad" or the "Company" (NYSE: BIO) breached their fiduciary duties to shareholders.
BIO: 118.36 (+0.79)
Ryan & Maniskas, LLP Announces Investigation of Bio-Rad Laboratories, Inc.
PR Newswire - Wed Nov 05, 6:30PM CST
Ryan & Maniskas, LLP has commenced an investigation into potential securities law violations by certain officers of Bio-Rad Laboratories, Inc. ("Bio-Rad" or the "Company" (NYSE: BIO).
BIO: 118.36 (+0.79)
BIO-RAD INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates Bio-Rad Laboratories, Inc. Following Bribery Settlement with Securities and Exchange Commission and the U.S. Department of Justice
Business Wire - Wed Nov 05, 3:58PM CST
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq. a partner at the law firm of Kahn Swick & Foti, LLC ("KSF" announces that KSF has commenced an investigation into Bio-Rad Laboratories, Inc. (NYSE: BIO).
BIO: 118.36 (+0.79)
Zacks Rank #5 Additions for Friday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 06, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Friday
AXE: 76.07 (+0.44), BIO: 118.36 (+0.79), BCE: 44.74 (+0.14), BITA: 62.95 (+2.85)
Bio-Rad to Report Fourth-Quarter and Full-Year 2014 Financial Results Thursday, February 26, 2015
Marketwired - Tue Feb 03, 5:57PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO.
, a global provider of life science research and clinical diagnostic products, will report financial results for the fourth quarter and full year 2014 on Thursday, February 26, 2015, after the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Standard Time (5 PM Eastern Standard Time) that day. BIO: 118.36 (+0.79), BIO.B: 117.35 (unch)
Frost & Sullivan Recognizes Bio-Rad's Digital PCR Platform, the QX200(TM) AutoDG(TM) Droplet Digital(TM) PCR System For New Product Innovation
PR Newswire Europe - Wed Jan 28, 8:00AM CST
-- Bio-Rad's Automated Droplet Generator delivers trusted, high-quality results to a market characterized by increasingly stringent regulations and standards
BIO: 118.36 (+0.79)
Affymetrix's Preliminary Q4 Revenues Outshine Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 13, 4:35PM CST
Affymetrix Inc (AFFX) recently announced preliminary revenue expectation for the fourth quarter of 2014.
A: 40.15 (+0.13), BIO: 118.36 (+0.79), ILMN: 198.54 (+1.81), AFFX: 11.45 (+0.02)
Zacks Rank #5 Additions for Tuesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 13, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Tuesday
CRR: 40.35 (+2.73), COG: 28.10 (+0.18), BIO: 118.36 (+0.79), ARPI: 17.95 (-0.04), AEG: 7.55 (-0.08)
Affymetrix (AFFX) Touches 52-Week High on Bullish Trends - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 29, 8:02AM CST
Shares of Affymetrix Inc. (AFFX) scaled a 52-week high of $10.14 on Dec 26 and closed at $10.07, representing a healthy year-to-date return of approximately 14.4%, better than the S&P 500's return of 12.6% over the same period.
A: 40.15 (+0.13), BIO: 118.36 (+0.79), ILMN: 198.54 (+1.81), AFFX: 11.45 (+0.02)
Affymetrix, Binding Site Group Ink Distribution Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 04, 4:25PM CST
Provider of life science tools and molecular diagnostic products, Affymetrix Inc. (AFFX), recently announced that its eBioscience business has entered into a multi-year distribution agreement with The Binding Site Group Ltd.
HBIO: 5.31 (-0.01), BIO: 118.36 (+0.79), ILMN: 198.54 (+1.81), AFFX: 11.45 (+0.02)
Affymetrix Axiom Genotyping Platform Selected by Toshiba - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 02, 5:10PM CST
The Axiom Genotyping Solution platform of Affymetrix (AFFX) has been selected by Toshiba's Healthcare Company as the platform for its newly launched genotyping service.
HBIO: 5.31 (-0.01), BIO: 118.36 (+0.79), ILMN: 198.54 (+1.81), AFFX: 11.45 (+0.02)
Zacks Rank #5 Additions for Wednesday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 26, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Wednesday
BUD: 121.72 (-0.80), BIO: 118.36 (+0.79), AVHI: 15.16 (+0.04), BBL: 48.82 (+2.36), WBAI: 17.36 (-0.30)
Bio-Rad Receives Premarket Application Approval for Its Geenius HIV 1/2 Supplemental Assay
Marketwired - Wed Nov 19, 3:45PM CST
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.
, a global provider of life science research and clinical diagnostic products life science research and clinical diagnostic products, today announced that it has received Premarket Application approval from the U.S. Food and Drug Administration for Bio-Rad's Geenius(TM) HIV 1/2 Supplemental Assay (test). BIO: 118.36 (+0.79), BIO.B: 117.35 (unch)
SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into Possible Breaches of Fiduciary Duty by the Board of Directors of Bio-Rad Laboratories, Inc.
PR Newswire - Wed Nov 12, 12:44PM CST
Levi & Korsinsky, LLP is investigating Bio-Rad Laboratories, Inc. ("Bio-Rad" or the "Company"
(NYSE: BIO) in connection with possible breaches of fiduciary duty by the Board of Directors of the Company. BIO: 118.36 (+0.79)
Lifshitz & Miller Law Firm Announces Investigation of Barrett Business Services, Inc., Bio-Rad Laboratories, Inc., Pingtan Marine Enterprise Ltd., Rayonier Inc. and Salix Pharmaceuticals, Ltd.
PR Newswire - Tue Nov 11, 11:10AM CST
Barrett Business Services, Inc.
RYN: 28.02 (-1.15), BIO: 118.36 (+0.79), BBSI: 39.78 (+0.84), SLXP: 152.35 (+3.17), PME: 2.42 (-0.07)
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces an Investigation into Possible Breaches of Fiduciary Duties by the Board of Directors of Bio-Rad Laboratories, Inc.
Business Wire - Fri Nov 07, 3:39PM CST
Rigrodsky & Long, P.A. announces that it is investigating whether certain officers and directors of Bio-Rad Laboratories, Inc. ("Bio-Rad" or the "Company"
(NYSE: BIO) breached their fiduciary duties to shareholders. BIO: 118.36 (+0.79)
Ryan & Maniskas, LLP Announces Investigation of Bio-Rad Laboratories, Inc.
PR Newswire - Wed Nov 05, 6:30PM CST
Ryan & Maniskas, LLP has commenced an investigation into potential securities law violations by certain officers of Bio-Rad Laboratories, Inc. ("Bio-Rad" or the "Company"
(NYSE: BIO). BIO: 118.36 (+0.79)
BIO-RAD INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates Bio-Rad Laboratories, Inc. Following Bribery Settlement with Securities and Exchange Commission and the U.S. Department of Justice
Business Wire - Wed Nov 05, 3:58PM CST
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq. a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"
announces that KSF has commenced an investigation into Bio-Rad Laboratories, Inc. (NYSE: BIO). BIO: 118.36 (+0.79)
